IN BRIEF: PureTech Health's Sonde Health signs deal for COPD in India

Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Says its founded entity, Sonde Health, has signed a multi-year agreement with specialty pharmaceutical company Koye Pharmaceuticals Pvt Ltd. The agreement is to develop a new vocal biomarker detection and monitoring capability for chronic obstructive pulmonary disease in India. This is Sonde's first partnership with a pharmaceutical firm, PureTech adds.

Current stock price: 248.00 pence

12-month change: down 25%

Copyright 2022 Alliance News Limited. All Rights Reserved.